🏛️ Verified NIH Record • Updated 2026-07-23
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (NCT05983250)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Tenax Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Who can join: Review the eligibility criteria below.
Location: Tenax Investigational Site — Tucson, Arizona
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- Tenax Investigational Site — Tucson, Arizona
- Tenax Investigational Site — La Jolla, California
- Tenax Investigational Site — Los Angeles, California
- Tenax Investigational Site — Los Angeles, California
- Tenax Investigational Site — Sacramento, California
- Tenax Investigational Site — San Francisco, California
- Tenax Investigational Site — Torrance, California
- Tenax Investigational Site — Jacksonville, Florida
- Tenax Investigational Site — Winter Haven, Florida
- Tenax Investigational Site — Atlanta, Georgia
- Tenax Investigational Site — Chicago, Illinois
- Tenax Investigational Site — Chicago, Illinois
- Tenax Investigational Site — Galesburg, Illinois
- Tenax Investigational Site — Indianapolis, Indiana
- Tenax Investigational Site — Indianapolis, Indiana
- Tenax Investigational Site — Louisville, Kentucky
- Tenax Investigational Site — Boston, Massachusetts
- Tenax Investigational Site — Minneapolis, Minnesota
- Tenax Investigational Site — Rochester, Minnesota
- Tenax Investigational Site — St Louis, Missouri
- Tenax Investigational Site — Omaha, Nebraska
- Tenax Investigational Site — New York, New York
- Tenax Investigational Site — New York, New York
- Tenax Investigational Site — Rochester, New York
- Tenax Investigational Site — Roslyn, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.